HNSCC
MCID: OBS525
MIFTS: 58

Obsolete: Squamous Cell Carcinoma of Head and Neck (HNSCC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards integrated aliases for Obsolete: Squamous Cell Carcinoma of Head and Neck:

Name: Obsolete: Squamous Cell Carcinoma of Head and Neck 59
Head and Neck Squamous Cell Carcinoma 59
Hnscc 59

Characteristics:

Orphanet epidemiological data:

59
obsolete: squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Orphanet 59 ORPHA67037

Summaries for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards based summary : Obsolete: Squamous Cell Carcinoma of Head and Neck, also known as head and neck squamous cell carcinoma, is related to papilloma and skin squamous cell carcinoma. An important gene associated with Obsolete: Squamous Cell Carcinoma of Head and Neck is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cevimeline and Raltitrexed have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Obsolete: Squamous Cell Carcinoma of Head and Neck

Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 387)
# Related Disease Score Top Affiliating Genes
1 papilloma 31.2 TP53 PTEN FGFR3
2 skin squamous cell carcinoma 30.5 TP53 PIK3CA MAP2K2 HRAS
3 paronychia 30.5 HRAS EGFR
4 breast squamous cell carcinoma 30.4 TP53 PIK3CA EGFR
5 adenosquamous carcinoma 30.4 TP53 PIK3CA EGFR
6 acneiform dermatitis 30.4 PIK3CA HRAS EGFR
7 thymoma 30.3 TP53 HRAS EGFR
8 lung benign neoplasm 30.3 TP53 HRAS EGFR
9 glioblastoma multiforme 30.3 TP53 PTEN PIK3CA EGFR
10 small cell carcinoma 30.1 TP53 PTEN EGFR
11 myeloma, multiple 29.9 TP53 IDH2 HRAS FGFR3 BRAF
12 nasopharyngeal carcinoma 29.8 TP53 PIK3CA HRAS EGFR
13 oral cavity cancer 29.8 TP53 TNFRSF10B PTEN PIK3CA EGFR
14 gastrointestinal stromal tumor 29.7 TP53 PTEN EGFR BRAF
15 pharynx cancer 29.6 TP53 EGFR CTNNB1
16 familial adenomatous polyposis 29.4 TP53 SMAD4 CTNNB1
17 breast adenocarcinoma 29.3 TP53 SMAD4 PTEN PIK3CA EGFR
18 glioma 29.3 TP53 PTEN PIK3CA IDH2 EGFR BRAF
19 glioblastoma 29.1 TP53 PTEN PIK3CA IDH2 HRAS EGFR
20 adenoma 29.1 TP53 SMAD4 GNAS CTNNB1 BRAF
21 adenoid cystic carcinoma 29.0 TP53 PTEN PIK3CA HRAS CTNNB1
22 colorectal adenocarcinoma 28.9 TP53 HRAS EGFR CTNNB1 BRAF
23 lung squamous cell carcinoma 28.8 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
24 pancreatic cancer 28.4 TP53 SMAD4 PIK3CA HRAS EGFR CTNNB1
25 esophageal cancer 28.2 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
26 gastric cancer 28.2 TP53 SMAD4 PTEN PIK3CA EGFR CTNNB1
27 endometrial cancer 27.9 TP53 PTEN PIK3CA HRAS EGFR CTNNB1
28 lung cancer 27.8 TP53 TNFRSF10B PTEN PIK3CA HRAS FGFR3
29 squamous cell carcinoma 27.8 TP53 SMAD4 PTEN PIK3CA ING1 HRAS
30 prostate cancer 27.7 TP53 TNFRSF10B PTEN PIK3CA HRAS EGFR
31 squamous cell carcinoma, head and neck 27.1 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
32 breast cancer 26.9 TP53 SMAD4 PTEN PIK3CA ING1 HRAS
33 adenocarcinoma 26.8 TP53 SMAD4 PTEN PIK3CA HRAS GNAS
34 lung cancer susceptibility 3 26.5 TP53 SMAD4 PIK3CA NFE2L2 HRAS GNAS
35 hepatocellular carcinoma 26.5 TP53 SMAD4 PTEN PIK3CA NFE2L2 IDH2
36 cervical cancer 26.4 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
37 gastric adenocarcinoma 26.3 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
38 colorectal cancer 25.3 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
39 oropharynx cancer 11.6
40 nevus of ota 10.7 TP53 BRAF
41 retinoblastoma 10.7
42 familial retinoblastoma 10.7
43 rare adenocarcinoma of the breast 10.7 TP53 PIK3CA
44 dermatosis papulosa nigra 10.7 PIK3CA FGFR3
45 malignant spiradenoma 10.7 TP53 PIK3CA
46 squamous cell papilloma 10.6
47 apocrine adenoma 10.6 PIK3CA HRAS
48 hyperplastic polyposis syndrome 10.6 TP53 BRAF
49 bladder squamous cell carcinoma 10.6 TP53 BRAF
50 non-invasive bladder papillary urothelial neoplasm 10.6 TP53 FGFR3

Graphical network of the top 20 diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck:



Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck

Symptoms & Phenotypes for Obsolete: Squamous Cell Carcinoma of Head and Neck

GenomeRNAi Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 BRAF EGFR HRAS PIK3CA
2 Decreased viability GR00221-A-1 10.3 EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-2 10.3 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.3 HRAS
5 Decreased viability GR00221-A-4 10.3 BRAF EGFR PIK3CA
6 Decreased viability GR00301-A 10.3 BRAF
7 Decreased viability GR00381-A-1 10.3 BRAF
8 Decreased viability GR00402-S-2 10.3 BRAF EGFR HRAS PIK3CA
9 Decreased viability in esophageal squamous lineage GR00235-A 10.03 BRAF CTNNB1 FGFR3 GNAS HRAS IDH2
10 Decreased cell migration GR00055-A-1 9.98 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 EGFR FGFR3 HRAS PTEN
12 Increased cell death HMECs cells GR00103-A-0 9.63 CTNNB1 EGFR MAP2K2 PIK3CA PTEN TP53
13 Decreased sensitivity to paclitaxel GR00112-A-0 9.37 PTEN SMAD4
14 Increased cell migration GR00055-A-3 9.35 BRAF CTNNB1 EGFR HRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.23 BRAF EGFR GNAS HRAS IDH2 NFE2L2

MGI Mouse Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BRAF CTNNB1 FGFR3 GNAS HRAS ING1
2 cardiovascular system MP:0005385 10.41 BRAF CTNNB1 EGFR GNAS HRAS IDH2
3 cellular MP:0005384 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
4 growth/size/body region MP:0005378 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.38 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
6 endocrine/exocrine gland MP:0005379 10.34 BRAF CTNNB1 EGFR GNAS HRAS ING1
7 integument MP:0010771 10.33 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
8 craniofacial MP:0005382 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
9 mortality/aging MP:0010768 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
10 neoplasm MP:0002006 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
11 digestive/alimentary MP:0005381 10.31 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
12 immune system MP:0005387 10.3 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
13 hematopoietic system MP:0005397 10.27 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
14 adipose tissue MP:0005375 10.24 BRAF EGFR GNAS MAP2K2 NFE2L2 PIK3CA
15 embryo MP:0005380 10.21 BRAF CTNNB1 EGFR NFE2L2 PIK3CA PTEN
16 nervous system MP:0003631 10.2 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
17 limbs/digits/tail MP:0005371 10.14 BRAF CTNNB1 EGFR FGFR3 GNAS PTEN
18 normal MP:0002873 10.14 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
19 hearing/vestibular/ear MP:0005377 10.13 BRAF CTNNB1 EGFR FGFR3 GNAS MAP2K2
20 liver/biliary system MP:0005370 10.13 BRAF CTNNB1 EGFR GNAS NFE2L2 PTEN
21 muscle MP:0005369 10.1 BRAF CTNNB1 EGFR GNAS PIK3CA PTEN
22 renal/urinary system MP:0005367 10.02 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
23 no phenotypic analysis MP:0003012 9.98 CTNNB1 EGFR FGFR3 GNAS HRAS PIK3CA
24 reproductive system MP:0005389 9.86 BRAF CTNNB1 EGFR FGFR3 PIK3CA PTEN
25 respiratory system MP:0005388 9.81 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
26 pigmentation MP:0001186 9.77 BRAF CTNNB1 EGFR PTEN TP53
27 skeleton MP:0005390 9.73 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
28 vision/eye MP:0005391 9.23 BRAF CTNNB1 EGFR FGFR3 MAP2K2 PIK3CA

Drugs & Therapeutics for Obsolete: Squamous Cell Carcinoma of Head and Neck

Drugs for Obsolete: Squamous Cell Carcinoma of Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 335)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cevimeline Approved Phase 4 107233-08-9 25137844 83898
2
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
3 Cholinergic Agents Phase 4
4 Muscarinic Agonists Phase 4
5
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
6
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
7
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
8
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
9
Dapsone Approved, Investigational Phase 3 80-08-0 2955
10
Metformin Approved Phase 3 657-24-9 4091 14219
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
leucovorin Approved Phase 3 58-05-9 143 6006
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Durvalumab Approved, Investigational Phase 3 1428935-60-7
16
afatinib Approved Phase 3 439081-18-2, 850140-72-6 10184653
17
Pentetic acid Approved Phase 3 67-43-6
18
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
19
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Tirapazamine Investigational Phase 3 27314-97-2
22
Zalutumumab Investigational Phase 3 667901-13-5, 828933-61-3
23 Tocotrienol Investigational Phase 3 6829-55-6
24
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
25 Nimorazole Investigational Phase 3 6506-37-2
26 Endostatins Phase 3 71581480
27 interferons Phase 3
28 Interferon alpha-2 Phase 3
29 Interferon-alpha Phase 3
30 Antimalarials Phase 3
31 Antitubercular Agents Phase 3
32 Tocotrienols Phase 3
33 Tocopherols Phase 3
34 Hypoglycemic Agents Phase 3
35 Lugol's solution Phase 3
36 Tubulin Modulators Phase 3
37 Antimitotic Agents Phase 3
38 Mitogens Phase 3
39 Folic Acid Antagonists Phase 3
40 Vitamin B9 Phase 3
41 Folate Phase 3
42 Vitamin B Complex Phase 3
43 Angiogenesis Inhibitors Phase 3
44 Angiogenesis Modulating Agents Phase 3
45 Endothelial Growth Factors Phase 3
46 Immunoglobulin G Phase 3
47 Pharmaceutical Solutions Phase 3
48 Radiopharmaceuticals Phase 3
49 Dextrans Phase 3
50 Technetium Tc 99m Pentetate Phase 3

Interventional clinical trials:

(show top 50) (show all 612)
# Name Status NCT ID Phase Drugs
1 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
2 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
3 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
4 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
5 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
6 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
7 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
8 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
9 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
10 A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00206219 Phase 3 Gefitinib;methotrexate
11 Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
12 A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00460265 Phase 3 ARM 2;ARM 1
13 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
14 DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Completed NCT00496652 Phase 3 Zalutumumab
15 Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
16 Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
17 Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma Completed NCT00054561 Phase 3 isotretinoin
18 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
19 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
20 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Recruiting NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
21 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) Recruiting NCT03765918 Phase 3 Cisplatin 100 mg/m^2
22 Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy Recruiting NCT03700905 Phase 3 Neoadjuvant Nivolumab;Adjuvant Nivolumab;Adjuvant Nivolumab and Ipilimumab
23 A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03815903 Phase 3 Induction chemotherapy
24 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Recruiting NCT02661152 Phase 3 Nimorazole
25 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
26 A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02999087 Phase 3 Cetuximab;avelumab;Cisplatin
27 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
28 Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma Recruiting NCT02442375 Phase 3
29 Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin Recruiting NCT03340896 Phase 3 Docetaxel;Cisplatin;Fluorouracil
30 Phase 3 Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Standard of Care for Locoregional Recurrent Head/Neck Squamous Cell Carcinoma in Patients Who Have Failed After at Least Two Lines of Therapy Recruiting NCT03769506 Phase 3 Physician's Choice SOC
31 Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer Recruiting NCT00957086 Phase 3 Nimotuzumab;Placebo
32 A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) Recruiting NCT02998385 Phase 3 Cisplatin
33 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
34 Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT01864850 Phase 3
35 A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting NCT03358472 Phase 3 Pembrolizumab;Epacadostat;Cetuximab;Cisplatin;Carboplatin;5-Fluorouracil
36 A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412) Active, not recruiting NCT03040999 Phase 3 Placebo;Cisplatin
37 A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Active, not recruiting NCT01950689 Phase 3 Nimorazole
38 A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT02358031 Phase 3 Cisplatin;Carboplatin;5-FU
39 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy. Active, not recruiting NCT01856478 Phase 3 methotrexate;afatinib
40 A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02 Active, not recruiting NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
41 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
42 A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck. Active, not recruiting NCT01880359 Phase 3 Cisplatin;Placebo;Nimorazole
43 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux Active, not recruiting NCT00609284 Phase 3 cetuximab;Carboplatin, 5FU concomitant
44 Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation Active, not recruiting NCT01884623 Phase 3 Cetuximab;Methotrexate
45 A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT02252042 Phase 3 methotrexate;docetaxel
46 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Active, not recruiting NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin
47 Concurrent Hypofractionated Radiotherapy With Weekly Cisplatin in Locally Advanced Squamous Cell Carcinoma Head and Neck SCCHN Active, not recruiting NCT03880396 Phase 2, Phase 3
48 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Not yet recruiting NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
49 A Randomized Phase III Study on Maintenance Durvalumab vs Placebo Following Post-operative Concomitant Chemoradiation in Subjects With HPV-negative Squamous Cell Head and Neck Carcinoma (HNSCC) With High Risk of Recurrence Not yet recruiting NCT03673735 Phase 3 Durvalumab;Placebo;Cisplatin
50 A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma Terminated NCT02131155 Phase 3 Placebo;Afatinib

Search NIH Clinical Center for Obsolete: Squamous Cell Carcinoma of Head and Neck

Genetic Tests for Obsolete: Squamous Cell Carcinoma of Head and Neck

Anatomical Context for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards organs/tissues related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

41
Lymph Node, Lung, T Cells, Endothelial, Testes, Tongue, Salivary Gland

Publications for Obsolete: Squamous Cell Carcinoma of Head and Neck

Articles related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

(show top 50) (show all 7203)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 38 71
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 71
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 71
9721851 1998
4
Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence. 38
31265875 2019
5
A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth. 38
30468243 2019
6
SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. 38
31276435 2019
7
Similarities in mRNA expression of peripheral blood drug metabolizing enzymes and cancer marker genes with biopsy samples of head and neck cancer patients. 38
31002268 2019
8
Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study. 38
31116482 2019
9
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade. 38
31340724 2019
10
Detecting recurrent head and neck cancer using electronic nose technology: A feasibility study. 38
31012533 2019
11
Radiogenomics in head and neck cancer: correlation of radiomic heterogeneity and somatic mutations in TP53, FAT1 and KMT2D. 38
31123786 2019
12
Discretionary Transduction of MMP-Sensitized Tousled in Head and Neck Cancer. 38
31011632 2019
13
Role of integrin β1 as a biomarker of stemness in head and neck squamous cell carcinoma. 38
31422211 2019
14
The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma. 38
31422206 2019
15
Targeting the unfolded protein response in head and neck and oral cavity cancers. 38
31075256 2019
16
Impact on Health-Related Quality of Life of Induction Chemotherapy Compared With Concurrent Cisplatin and Radiation Therapy in Patients With Head and Neck Cancer. 38
31147146 2019
17
Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis. 38
30937621 2019
18
pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma. 38
31422204 2019
19
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. 38
31422205 2019
20
Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma. 38
31348981 2019
21
Clinical utility of 18F-FDG PET/CT for patients with recurrent head and neck squamous cell carcinoma. 38
31274365 2019
22
C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma. 38
30870229 2019
23
Chemoradiation and local recurrence of head and neck squamous cell carcinoma and the risk of carotid artery blowout. 38
31070287 2019
24
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues. 38
31379147 2019
25
Pembrolizumab for the treatment of head and neck squamous cell cancer. 38
31317798 2019
26
Exploring the role of Mir204/211 in HNSCC by the combination of bioinformatic analysis of ceRNA and transcription factor regulation. 38
31422208 2019
27
[Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)]. 38
31250051 2019
28
Lymphotoxin-α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3-dependent manner. 38
30785217 2019
29
QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth. 38
31026342 2019
30
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. 38
30694565 2019
31
Gold nanoclusters as a contrast agent for image-guided surgery of head and neck tumors. 38
31103735 2019
32
The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042. 38
31382448 2019
33
Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. 38
31345401 2019
34
Importance of the immune system in head and neck cancer. 38
30821023 2019
35
Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. 38
30835919 2019
36
CASP9 c.-1339A>G and CASP3 c.-1191A>G polymorphisms alter susceptibility and clinical aspects of head and neck squamous cell carcinoma. 38
30903678 2019
37
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy. 38
31427592 2019
38
Radioimmunotherapy for the treatment of head and neck cancer. 38
31364593 2019
39
High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells. 38
31394808 2019
40
Histogram Analysis Parameters Derived from Conventional T1- and T2-Weighted Images Can Predict Different Histopathological Features Including Expression of Ki67, EGFR, VEGF, HIF-1α, and p53 and Cell Count in Head and Neck Squamous Cell Carcinoma. 38
30284155 2019
41
Patterns of antibody responses to non-viral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. 38
31407331 2019
42
Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. 38
31048234 2019
43
Squamous cell carcinoma antigen concentration in fine needle aspiration samples: A new method to detect cervical lymph node metastases of head and neck squamous cell carcinoma. 38
30828886 2019
44
Neuregulin Signaling is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. 38
31387891 2019
45
Prediction of head and neck squamous cell carcinoma survival based on the expression of 15 lncRNAs. 38
30927266 2019
46
Prognostic value of the nodal yield in head and neck squamous cell carcinoma: A systematic review. 38
30969454 2019
47
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. 38
30828910 2019
48
A gene signature associated with prognosis and immune processes in head and neck squamous cell carcinoma. 38
30839132 2019
49
MRI-based radiomic signature as predictive marker for patients with head and neck squamous cell carcinoma. 38
31307647 2019
50
Altered DNA methylation is associated with aberrant stemness gene expression in early‑stage HNSCC. 38
31432153 2019

Variations for Obsolete: Squamous Cell Carcinoma of Head and Neck

ClinVar genetic disease variations for Obsolete: Squamous Cell Carcinoma of Head and Neck:

6 (show top 50) (show all 344)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.5(TP53): c.832C> A (p.Pro278Thr) single nucleotide variant Likely pathogenic,drug response rs17849781 17:7577106-7577106 17:7673788-7673788
2 EGFR NM_005228.5(EGFR): c.2155G> C (p.Gly719Arg) single nucleotide variant Likely pathogenic,drug response rs28929495 7:55241707-55241707 7:55174014-55174014
3 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
4 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic rs148924904 17:7578442-7578442 17:7675124-7675124
5 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
6 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic rs587781288 17:7578508-7578508 17:7675190-7675190
7 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
8 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
9 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
10 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
11 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
12 IDH2 NM_002168.3(IDH2): c.419G> A (p.Arg140Gln) single nucleotide variant Pathogenic rs121913502 15:90631934-90631934 15:90088702-90088702
13 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
14 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 4:1803568-1803568 4:1801841-1801841
15 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic rs377767347 18:48591919-48591919 18:51065549-51065549
16 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
17 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
18 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic rs587782289 17:7577575-7577575 17:7674257-7674257
19 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
20 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
21 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic rs876659802 17:7577105-7577105 17:7673787-7673787
22 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
23 TP53 NM_000546.5(TP53): c.517G> T (p.Val173Leu) single nucleotide variant Pathogenic rs876660754 17:7578413-7578413 17:7675095-7675095
24 TNFRSF10B TNFRSF10B, 2-BP INS insertion Pathogenic
25 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
26 PTEN NM_000314.7(PTEN): c.362C> G (p.Ala121Gly) single nucleotide variant Pathogenic rs121909237 10:89692878-89692878 10:87933121-87933121
27 ING1 NM_198217.2(ING1): c.512G> C (p.Cys171Ser) single nucleotide variant Pathogenic rs121909250 13:111372083-111372083 13:110719736-110719736
28 ING1 NM_198217.2(ING1): c.515A> G (p.Asn172Ser) single nucleotide variant Pathogenic rs121909251 13:111372086-111372086 13:110719739-110719739
29 ING1 NM_198217.2(ING1): c.443C> A (p.Ala148Asp) single nucleotide variant Pathogenic rs121909252 13:111372014-111372014 13:110719667-110719667
30 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 19:4117551-4117551 19:4117553-4117553
31 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 18:48591918-48591918 18:51065548-51065548
32 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
33 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
34 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
35 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
36 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
37 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
38 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
39 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
40 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
41 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
42 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
43 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
44 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
45 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
46 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
47 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
48 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
49 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
50 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075

Expression for Obsolete: Squamous Cell Carcinoma of Head and Neck

Search GEO for disease gene expression data for Obsolete: Squamous Cell Carcinoma of Head and Neck.

Pathways for Obsolete: Squamous Cell Carcinoma of Head and Neck

Pathways related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 147)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MAP2K2
2
Show member pathways
13.92 TP53 TNFRSF10B PTEN MAP2K2 HRAS GNAS
3
Show member pathways
13.92 TP53 TNFRSF10B SMAD4 PTEN MAP2K2 HRAS
4
Show member pathways
13.77 TP53 SMAD4 MAP2K2 HRAS GNAS FGFR3
5
Show member pathways
13.76 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
6
Show member pathways
13.75 TP53 TNFRSF10B SMAD4 MAP2K2 HRAS GNAS
7
Show member pathways
13.63 SMAD4 MAP2K2 HRAS GNAS FGFR3 EGFR
8
Show member pathways
13.61 TP53 TNFRSF10B SMAD4 PIK3CA MAP2K2 HRAS
9
Show member pathways
13.58 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
10
Show member pathways
13.48 TP53 TNFRSF10B PTEN HRAS GNAS FGFR3
11
Show member pathways
13.48 PTEN PIK3CA MAP2K2 HRAS GNAS EGFR
12
Show member pathways
13.43 TP53 PIK3CA MAP2K2 HRAS FGFR3 EGFR
13
Show member pathways
13.38 TNFRSF10B SMAD4 PTEN HRAS FGFR3 EGFR
14
Show member pathways
13.37 PTEN MAP2K2 HRAS GNAS FGFR3 EGFR
15
Show member pathways
13.36 MAP2K2 HRAS GNAS FGFR3 EGFR CTNNB1
16
Show member pathways
13.3 TP53 PTEN MAP2K2 HRAS GNAS EGFR
17
Show member pathways
13.16 TP53 PTEN MAP2K2 HRAS GNAS FGFR3
18
Show member pathways
13.12 MAP2K2 HRAS GNAS EGFR CTNNB1 BRAF
19
Show member pathways
13.1 TP53 MAP2K2 HRAS GNAS CTNNB1 BRAF
20
Show member pathways
13.09 MAP2K2 HRAS GNAS FGFR3 EGFR
21
Show member pathways
13.08 PIK3CA MAP2K2 HRAS GNAS EGFR
22
Show member pathways
13.05 TP53 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS
23
Show member pathways
13.05 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
24
Show member pathways
13.04 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
25
Show member pathways
13.02 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS GNAS
26
Show member pathways
13.01 PTEN PIK3CA MAP2K2 HRAS EGFR CTNNB1
27
Show member pathways
13 PTEN PIK3CA MAP2K2 HRAS EGFR BRAF
28
Show member pathways
12.98 PTEN MAP2K2 HRAS CTNNB1 BRAF
29
Show member pathways
12.97 PTEN PIK3CA MAP2K2 HRAS GNAS FGFR3
30
Show member pathways
12.89 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS
31
Show member pathways
12.89 MAP2K2 HRAS GNAS CTNNB1 BRAF
32
Show member pathways
12.89 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
33 12.87 TP53 MAP2K2 HRAS FGFR3 EGFR BRAF
34
Show member pathways
12.86 PTEN PIK3CA MAP2K2 HRAS BRAF
35
Show member pathways
12.83 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
36
Show member pathways
12.83 TP53 PTEN PIK3CA MAP2K2 HRAS CTNNB1
37
Show member pathways
12.82 PIK3CA MAP2K2 HRAS GNAS FGFR3 EGFR
38
Show member pathways
12.77 TP53 MAP2K2 HRAS EGFR BRAF
39
Show member pathways
12.76 MAP2K2 HRAS GNAS EGFR BRAF
40 12.75 PIK3CA MAP2K2 HRAS FGFR3 EGFR BRAF
41
Show member pathways
12.73 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS GNAS
42
Show member pathways
12.72 TP53 PIK3CA MAP2K2 HRAS EGFR BRAF
43
Show member pathways
12.7 TP53 PIK3CA HRAS EGFR CTNNB1
44
Show member pathways
12.68 PIK3CA MAP2K2 HRAS GNAS EGFR
45 12.65 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
46
Show member pathways
12.65 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
47
Show member pathways
12.64 PTEN PIK3CA MAP2K2 HRAS
48
Show member pathways
12.63 PIK3CA HRAS FGFR3 BRAF
49
Show member pathways
12.62 TNFRSF10B PIK3CA MAP2K2 HRAS BRAF
50
Show member pathways
12.59 PTEN PIK3CA MAP2K2 HRAS

GO Terms for Obsolete: Squamous Cell Carcinoma of Head and Neck

Cellular components related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 TP53 SMAD4 PTEN NFE2L2 MAP2K2 ING1
2 perinuclear region of cytoplasm GO:0048471 9.72 MAP2K2 HRAS GNAS EGFR CTNNB1
3 cytosol GO:0005829 9.32 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
4 intracellular GO:0005622 8.65 SMAD4
5 cytoplasm GO:0005737 10.03 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2

Biological processes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.99 PIK3CA MAP2K2 FGFR3 EGFR BRAF
2 protein phosphorylation GO:0006468 9.97 PIK3CA MAP2K2 FGFR3 EGFR BRAF
3 positive regulation of cell proliferation GO:0008284 9.95 PTEN HRAS FGFR3 EGFR CTNNB1
4 positive regulation of apoptotic process GO:0043065 9.92 TP53 TNFRSF10B PTEN CTNNB1
5 negative regulation of apoptotic process GO:0043066 9.85 TP53 PTEN EGFR CTNNB1 BRAF
6 negative regulation of cell proliferation GO:0008285 9.85 TP53 SMAD4 PTEN ING1 HRAS CTNNB1
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 PTEN HRAS FGFR3 EGFR BRAF
8 T cell receptor signaling pathway GO:0050852 9.81 PIK3CA HRAS BRAF
9 peptidyl-tyrosine phosphorylation GO:0018108 9.81 MAP2K2 FGFR3 EGFR BRAF
10 cellular response to hypoxia GO:0071456 9.8 TP53 PTEN NFE2L2
11 negative regulation of cell growth GO:0030308 9.8 TP53 SMAD4 ING1
12 regulation of cell proliferation GO:0042127 9.8 SMAD4 EGFR CTNNB1 BRAF
13 MAPK cascade GO:0000165 9.8 MAP2K2 HRAS FGFR3 EGFR BRAF
14 positive regulation of gene expression GO:0010628 9.8 TP53 PTEN NFE2L2 HRAS CTNNB1 BRAF
15 response to estradiol GO:0032355 9.76 PTEN EGFR CTNNB1
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 PIK3CA EGFR BRAF
17 positive regulation of MAPK cascade GO:0043410 9.65 HRAS FGFR3 CTNNB1
18 gastrulation with mouth forming second GO:0001702 9.64 SMAD4 CTNNB1
19 positive regulation of histone H3-K4 methylation GO:0051571 9.61 SMAD4 CTNNB1
20 cellular response to drug GO:0035690 9.56 TP53 NFE2L2 EGFR BRAF
21 cell proliferation GO:0008283 9.55 TP53 SMAD4 PTEN EGFR CTNNB1
22 regulation of axon regeneration GO:0048679 9.54 PTEN BRAF
23 hair follicle placode formation GO:0060789 9.52 GNAS CTNNB1
24 positive regulation of transcription, DNA-templated GO:0045893 9.5 TP53 SMAD4 NFE2L2 MAP2K2 ING1 EGFR
25 phosphatidylinositol phosphorylation GO:0046854 9.3 PIK3CA
26 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.8 TP53 MAP2K2 EGFR
27 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 TP53 SMAD4 NFE2L2 HRAS EGFR CTNNB1
28 apoptotic process GO:0006915 10 TP53 TNFRSF10B PTEN HRAS FGFR3

Molecular functions related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.93 TP53 SMAD4 PTEN FGFR3 EGFR BRAF
2 kinase activity GO:0016301 9.88 PIK3CA MAP2K2 FGFR3 EGFR BRAF
3 enzyme binding GO:0019899 9.8 TP53 PTEN EGFR CTNNB1
4 protein heterodimerization activity GO:0046982 9.72 TP53 SMAD4 EGFR CTNNB1 BRAF
5 protein phosphatase binding GO:0019903 9.58 TP53 EGFR CTNNB1
6 I-SMAD binding GO:0070411 9.43 SMAD4 CTNNB1
7 nucleotide binding GO:0000166 9.35 MAP2K2 HRAS FGFR3 EGFR BRAF
8 RNA polymerase II transcription factor binding GO:0001085 9.33 TP53 SMAD4 CTNNB1
9 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.96 PIK3CA
10 protein tyrosine kinase activity GO:0004713 8.92 MAP2K2 FGFR3 EGFR BRAF
11 protein binding GO:0005515 10.21 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2

Sources for Obsolete: Squamous Cell Carcinoma of Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....